HFE mutations in Caucasian participants of the Hemochromatosis and Iron Overload Screening study with serum ferritin level <1000 μg/L

Canadian Journal of Gastroenterology

Volumn 27, Issue 7, 2013, Pages 390-392

  Adams, Paul C ^a   McLaren, Christine E ^b   Speechley, Mark ^c   McLaren, Gordon D ^b,d   Barton, James C ^e   Eckfeldt, John H ^f  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^e SOUTHERN IRON DISORDERS CENTER   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Ferritin; Haemochromatosis; Hemochromatosis; Iron overload

Indexed keywords

FERRITIN; TRANSFERRIN;

ADULT; ARTICLE; CAUCASIAN; FEMALE; FERRITIN BLOOD LEVEL; GENE; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HFE GENE; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; HYPERFERRITINEMIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL;

EID: 84879931036     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/493170     Document Type: Article

References (13)

1. Wong K, Adams PC. The diversity of liver diseases associated with an elevated serum ferritin. Can J Gastro 2007;20:467-70.
2. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005;352:1769-78. (Pubitemid 40570925)
3. McLaren CE, Barton JC, Adams PC, et al. Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci 2003;325:53-62. (Pubitemid 36236661)
4. Adams PC, Passmore L, Chakrabarti S, et al. Liver diseases in the Hemochromatosis and Iron Overload Screening Study. Clin Gastroenterol Hepatol 2006;4:918-23.
5. Acton RT, Barton JC, Passmore LV, et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 2006;29:2084-9. (Pubitemid 44871191)
6. Haynes RB, Sackett DL, Guyatt GH, Tugwell P. Clinical Epidemiology, 3rd edn. Philadelphia: Lippincott Williams and Wilkins; 2006:279.
7. Barton JC, Lafreniere SA, Leiendecker-Foster C, et al. HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 785 HEIRS study participants. Am J Hematol 2009;84:710-4.
8. Neghina AM, Anghel A. Hemochromatosis genotypes and risk of iron overload - a meta-analysis. Ann Epidemiol 2011;21:1-14.
9. Adams PC, Reboussin DM, Press RD, et al. Biological variability of transferrin saturation and unsaturated iron binding capacity. Am J Med 2007;120:999:e1-e7.
10. Mainous AG III, Diaz VA, Everett CJ, et al. IRon Overload screeNing tool (IRON): Development of a tool to guide screening in primary care. Am J Hematol 2011;86:733-7.
11. Waalen J, Felitti VJ, Gelbart T, et al. Screening for hemochromatosis by measuring ferritin levels: A more effective approach. Blood 2008;111:3373-6.
12. Allen KJ, Bertalli NA, Osborne NJ, et al. HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis. Hepatology 2010;52:925-33.
13. Barton JC, Barton JC, Acton RT, So J, Chan S, Adams PC. Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis. Clin Gastroenterol Hepatol 2012;10:412-6. Genome Research Institute, National Institute of Health